[
  {
    "ts": null,
    "headline": "BioNTech (BNTX) Faces Legal Challenges Over mRNA Patent",
    "summary": "BioNTech (BNTX) has been under scrutiny due to significant legal challenges, including a recent claim construction ruling in a patent lawsuit involving its COVID-19 mRNA vaccine technology. At the same time, the company has engaged in collaborations, such as the co-development agreement with Bristol-Myers Squibb, and reported positive trial results for various vaccines and therapies. Despite these developments, BioNTech's shares saw a price move of 9% decline last quarter. This decline...",
    "url": "https://finnhub.io/api/news?id=3e5047ff11aa2cf2ed7df5074c609aa570eacb9a9fdaff9901cbabbb61e880cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757788204,
      "headline": "BioNTech (BNTX) Faces Legal Challenges Over mRNA Patent",
      "id": 136736113,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BioNTech (BNTX) has been under scrutiny due to significant legal challenges, including a recent claim construction ruling in a patent lawsuit involving its COVID-19 mRNA vaccine technology. At the same time, the company has engaged in collaborations, such as the co-development agreement with Bristol-Myers Squibb, and reported positive trial results for various vaccines and therapies. Despite these developments, BioNTech's shares saw a price move of 9% decline last quarter. This decline...",
      "url": "https://finnhub.io/api/news?id=3e5047ff11aa2cf2ed7df5074c609aa570eacb9a9fdaff9901cbabbb61e880cc"
    }
  }
]